United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
United Therapeutics (NASDAQ: UTHR) has been recognized as one of the Fortune 100 Best Companies to Work For in 2025, ranking #73 on the prestigious list. The recognition comes from Great Place to Work® and Fortune magazine, based on confidential feedback from over 1.3 million U.S. employees.
As the first publicly-traded biotech company to become a public benefit (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and expanding transplantable organ availability. The company's placement on the list reflects its commitment to creating a high-trust workplace environment, measured through Great Place To Work's Trust Index™ Survey.
Michael Benkowitz, President & COO, emphasized the company's goal of being a destination employer, while Alyssa Friedrich, EVP and Chief People Officer, highlighted their focus on creating an environment where employees feel valued and inspired.
United Therapeutics (NASDAQ: UTHR) è stata riconosciuta come una delle 100 migliori aziende per cui lavorare nel 2025, classificandosi al #73 nella prestigiosa lista. Il riconoscimento proviene da Great Place to Work® e dalla rivista Fortune, basato su feedback riservati di oltre 1,3 milioni di dipendenti negli Stati Uniti.
Essendo la prima azienda biotech quotata in borsa a diventare una public benefit corporation (PBC), United Therapeutics si concentra sullo sviluppo di nuove terapie farmacologiche e sull'espansione della disponibilità di organi trapiantabili. La posizione dell'azienda nella lista riflette il suo impegno a creare un ambiente di lavoro ad alta fiducia, misurato attraverso il Trust Index™ Survey di Great Place To Work.
Michael Benkowitz, Presidente e COO, ha sottolineato l'obiettivo dell'azienda di essere un datore di lavoro di riferimento, mentre Alyssa Friedrich, EVP e Chief People Officer, ha evidenziato il loro impegno a creare un ambiente in cui i dipendenti si sentano valorizzati e ispirati.
United Therapeutics (NASDAQ: UTHR) ha sido reconocida como una de las 100 mejores empresas para trabajar en 2025, ocupando el puesto #73 en la prestigiosa lista. Este reconocimiento proviene de Great Place to Work® y la revista Fortune, basado en comentarios confidenciales de más de 1.3 millones de empleados en EE. UU.
Siendo la primera empresa biotech que cotiza en bolsa en convertirse en una public benefit corporation (PBC), United Therapeutics se centra en desarrollar nuevas terapias farmacéuticas y en ampliar la disponibilidad de órganos trasplantables. La inclusión de la empresa en la lista refleja su compromiso con la creación de un entorno laboral de alta confianza, medido a través de la encuesta Trust Index™ de Great Place To Work.
Michael Benkowitz, Presidente y COO, enfatizó el objetivo de la empresa de ser un empleador de referencia, mientras que Alyssa Friedrich, EVP y Chief People Officer, destacó su enfoque en crear un ambiente donde los empleados se sientan valorados e inspirados.
유나이티드 테라퓨틱스 (NASDAQ: UTHR)는 2025년 일하기 좋은 100대 기업 중 하나로 인정받아, 권위 있는 목록에서 73위에 올랐습니다. 이 인정은 그레이트 플레이스 투 워크(Great Place to Work®)와 포춘 매거진(Fortune)에서, 130만 명 이상의 미국 직원들의 비밀 피드백을 바탕으로 이루어졌습니다.
공개 이익 법인(public benefit corporation (PBC))으로 전환한 최초의 상장 생명공학 회사인 유나이티드 테라퓨틱스는 새로운 제약 치료법 개발과 이식 가능한 장기 가용성 확대에 집중하고 있습니다. 이 회사의 목록 등재는 그레이트 플레이스 투 워크의 신뢰 지수™ 조사로 측정된 높은 신뢰의 근무 환경 조성에 대한 헌신을 반영합니다.
마이클 벤코위츠(Michael Benkowitz) 사장 겸 COO는 회사의 목표가 매력적인 고용주가 되는 것이라고 강조했으며, 알리사 프리드리히(Alyssa Friedrich) EVP 겸 인사 책임자는 직원들이 존중받고 영감을 받을 수 있는 환경을 조성하는 데 집중하고 있다고 밝혔습니다.
United Therapeutics (NASDAQ: UTHR) a été reconnue comme l'une des 100 meilleures entreprises où travailler en 2025, se classant au 73e rang de cette prestigieuse liste. Cette reconnaissance provient de Great Place to Work® et du magazine Fortune, sur la base de retours confidentiels de plus de 1,3 million d'employés aux États-Unis.
En tant que première entreprise biotechnologique cotée en bourse à devenir une public benefit corporation (PBC), United Therapeutics se concentre sur le développement de nouvelles thérapies pharmaceutiques et l'augmentation de la disponibilité des organes transplantables. La position de l'entreprise sur la liste reflète son engagement à créer un environnement de travail de haute confiance, mesuré par l'enquête Trust Index™ de Great Place To Work.
Michael Benkowitz, Président et COO, a souligné l'objectif de l'entreprise d'être un employeur de choix, tandis qu'Alyssa Friedrich, EVP et Chief People Officer, a mis en avant leur volonté de créer un environnement où les employés se sentent valorisés et inspirés.
United Therapeutics (NASDAQ: UTHR) wurde als eines der 100 besten Unternehmen zum Arbeiten im Jahr 2025 ausgezeichnet und belegt Platz #73 auf der renommierten Liste. Die Auszeichnung stammt von Great Place to Work® und dem Fortune-Magazin und basiert auf vertraulichem Feedback von über 1,3 Millionen US-Mitarbeitern.
Als erstes börsennotiertes Biotech-Unternehmen, das eine Public Benefit Corporation (PBC) geworden ist, konzentriert sich United Therapeutics auf die Entwicklung neuartiger pharmazeutischer Therapien und die Erweiterung der Verfügbarkeit transplantierbarer Organe. Die Platzierung des Unternehmens auf der Liste spiegelt sein Engagement wider, ein vertrauensvolles Arbeitsumfeld zu schaffen, das durch die Trust Index™-Umfrage von Great Place To Work gemessen wird.
Michael Benkowitz, Präsident und COO, betonte das Ziel des Unternehmens, ein attraktiver Arbeitgeber zu sein, während Alyssa Friedrich, EVP und Chief People Officer, den Fokus auf die Schaffung eines Umfelds hervorhob, in dem sich die Mitarbeiter geschätzt und inspiriert fühlen.
- None.
- None.
“We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For,” said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. “This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients through the development of novel therapeutics and progress toward an unlimited supply of transplantable organs.”
“This achievement is a testament to the commitment of all our employees, the strength of our culture, and the unwavering belief that investing in our people is the key to driving innovation and success,” said Alyssa Friedrich, Executive Vice President and Chief People Officer of United Therapeutics. “We remain focused on creating an environment where everyone feels valued and inspired to bring their best selves to work every day.”
The 100 Best Companies list honors companies that build a high-trust workplace environment, measured through Great Place To Work’s proprietary survey platform. Confidential feedback from more than 1.3 million employees in the
The Fortune 100 Best Companies to Work For list is highly competitive. Companies are only considered for the list if they are a Great Place to Work Certified™ organization with 1,000 or more employees in the
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 2, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402793745/en/
For Further Information Contact:
Alyssa Friedrich at (240) 821-1730
afriedrich@unither.com
Source: United Therapeutics Corporation
FAQ
What ranking did United Therapeutics (UTHR) achieve in Fortune's 100 Best Companies to Work For 2025?
How does United Therapeutics qualify for the Fortune 100 Best Companies list?
What is United Therapeutics' public benefit purpose as a PBC?
How many employees participated in the survey that led to UTHR's Fortune 100 recognition?
What distinguishes United Therapeutics in the pharmaceutical industry?
